[go: up one dir, main page]

WO2006108651A3 - Use of activin products for preventing and treating diabetes and/or metabolic syndrome - Google Patents

Use of activin products for preventing and treating diabetes and/or metabolic syndrome Download PDF

Info

Publication number
WO2006108651A3
WO2006108651A3 PCT/EP2006/003397 EP2006003397W WO2006108651A3 WO 2006108651 A3 WO2006108651 A3 WO 2006108651A3 EP 2006003397 W EP2006003397 W EP 2006003397W WO 2006108651 A3 WO2006108651 A3 WO 2006108651A3
Authority
WO
WIPO (PCT)
Prior art keywords
metabolic syndrome
activin
preventing
products
treating diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/003397
Other languages
French (fr)
Other versions
WO2006108651A2 (en
Inventor
Rainer Mussmann
Tri Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Develogen AG
Original Assignee
Develogen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen AG filed Critical Develogen AG
Publication of WO2006108651A2 publication Critical patent/WO2006108651A2/en
Publication of WO2006108651A3 publication Critical patent/WO2006108651A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

This invention relates to the use of activin proteins, to the use of polynucleotides encoding these, and to the use of modulators/effectors thereof in the prevention, and/or treatment of pancreatic disorders such as diabetes mellitus and/or metabolic syndrome or in the prevention and/or treatment of neurodegenerative disorders. More particularly, this invention relates to the use of activin proteins in combination with a neurotrophin proteins, to the use of polynucleotides encoding these, and to the use of modulators/effectors thereof in the prevention, and treatment of pancreatic disorders such as diabetes mellitus and/or metabolic syndrome and in the prevention and/or treatment of neurodegenerative disorders.
PCT/EP2006/003397 2005-04-12 2006-04-12 Use of activin products for preventing and treating diabetes and/or metabolic syndrome Ceased WO2006108651A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05007976.3 2005-04-12
EP05007976 2005-04-12

Publications (2)

Publication Number Publication Date
WO2006108651A2 WO2006108651A2 (en) 2006-10-19
WO2006108651A3 true WO2006108651A3 (en) 2007-06-28

Family

ID=34935036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/003397 Ceased WO2006108651A2 (en) 2005-04-12 2006-04-12 Use of activin products for preventing and treating diabetes and/or metabolic syndrome

Country Status (1)

Country Link
WO (1) WO2006108651A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015038582A2 (en) * 2013-09-11 2015-03-19 New York University Methods and compositions for treating bone diseases
CN104353059A (en) * 2014-10-15 2015-02-18 南方医科大学 Application of Activin A in preparation of medicine for treating withdrawal symptoms after mental excitation type drug addiction
CN104353060A (en) * 2014-10-15 2015-02-18 南方医科大学 Application of Activin B in preparation of medicine for treating neurodegeneration diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003569A1 (en) * 1989-08-30 1991-03-21 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Neurotrophin-3, a novel neurotrophic factor related to nerve growth factor and brain derived neurotrophic factor
WO1999015192A1 (en) * 1997-09-19 1999-04-01 Auckland Uniservices Limited Neuronal rescue agent
EP1010432A1 (en) * 1997-01-23 2000-06-21 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes
WO2002086107A2 (en) * 2001-04-19 2002-10-31 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung A method for differentiating stem cells into insulin-producing cells
WO2003100026A2 (en) * 2002-05-28 2003-12-04 Novocell, Inc. Methods, compositions, and growth and differentiation factors for insulin-producing cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003569A1 (en) * 1989-08-30 1991-03-21 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Neurotrophin-3, a novel neurotrophic factor related to nerve growth factor and brain derived neurotrophic factor
EP1010432A1 (en) * 1997-01-23 2000-06-21 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes
WO1999015192A1 (en) * 1997-09-19 1999-04-01 Auckland Uniservices Limited Neuronal rescue agent
WO2002086107A2 (en) * 2001-04-19 2002-10-31 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung A method for differentiating stem cells into insulin-producing cells
WO2003100026A2 (en) * 2002-05-28 2003-12-04 Novocell, Inc. Methods, compositions, and growth and differentiation factors for insulin-producing cells

Also Published As

Publication number Publication date
WO2006108651A2 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
WO2005063232A8 (en) Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
CL2007003155A1 (en) COMPOUNDS DERIVED FROM 3,7-DIAZABICICLO [3.3.0] OCTANO OR 3,7-DIAZABICICLO [3.3.1] NONANO, NEURONAL NICOTINIC RECEIVER MODULATORS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CNS DISORDERS.
WO2008008887A3 (en) Gpr119 agonists for treating metabolic disorders
WO2008143954A3 (en) Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
WO2008070692A8 (en) Bicyclic compounds and use as antidiabetics
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2010092123A8 (en) Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
TW200740804A (en) Glucokinase activators
WO2006083491A3 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007075525A3 (en) Combination of an iap-inhibitor and a taxane7
WO2009051706A3 (en) Peptide compounds for treating obesity and insulin resistance
ZA200706294B (en) Roflumilast for the treatment of diabetes mellitus
WO2007079999A3 (en) Pyridopyrazine derivatives and use thereof as modulators of the signal transduction paths
WO2005118511A3 (en) Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
PL2083809T3 (en) Dietary or pharmaceutical compositions containing tricyclic diterpenes for the treatment of depression.
WO2008043566A3 (en) Compositions and methods for treating and diagnosing irritable bowel syndrome
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2007022385A3 (en) Use of cxcr4 binding molecules for the treatment of whim syndrome
WO2004024167A3 (en) Use of prebiotics, preferably glucooligosaccharide, for the prevention of the onset of type ii diabetes
WO2006089095A3 (en) Treating neurological disorders
WO2007149875A3 (en) Compositions and methods for treating, preventing and/or reversing type-1 diabetes
EP1879591B8 (en) Use of azapaullones for preventing and treating pancreatic autoimmune disorders
WO2006128041A3 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
WO2006108651A3 (en) Use of activin products for preventing and treating diabetes and/or metabolic syndrome
WO2005079840A3 (en) Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06724297

Country of ref document: EP

Kind code of ref document: A2